ArticleJournal of inflammation research2025
Comprehensive Analysis of Selenium Metabolism and Selenoproteins-Associated Gene Signatures in Ulcerative Colitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by persistent mucosal inflammation. Oxidative stress plays a vital role in UC pathogenesis. Selenium (Se), an essential trace element, functions via selenoproteins and metabolites. Selenocysteine (Sec), the 21st amino acid, is incorporated into selenoproteins with strong antioxidant and anti-inflammatory properties. However, the role of selenium metabolism and selenoproteins (SeMet) in UC remains poorly understood. Methods: Gene expression and clinical data from UC patients and healthy controls were obtained from the GEO database. SeMet-related gene sets were collected from Molecular Signatures Database (MSigDB). Weighted gene co-expression network analysis (WGCNA) and differential expression analysis identified key modules and genes associated with UC. Machine learning algorithms were used to screen signature genes and construct a UC risk prediction model. Single-cell RNA sequencing (scRNA-seq) was performed to examine gene expression at the cellular level. Expression of differentially regulated genes (DRGs) and signature genes was validated using quantitative polymerase chain reaction (qPCR), Western blotting, and immunohistochemistry (IHC). Results: DRGs were significantly upregulated in UC and used to classify 161 UC samples into two subtypes. Six candidate signature genes were identified by integrating WGCNA and machine learning, showing high diagnostic potential and inter-correlation. scRNA-seq revealed upregulation of many selenoproteins in epithelial cells and downregulation of SELENOP in immune cells. The six signature genes were consistently upregulated across multiple cell types. WARS1 (tryptophanyl-tRNA synthetase 1), one of the signature genes, responded strongly to oxidative stress, and its knockdown elevated inflammatory cytokine levels. Conclusion: SeMet-related genes are crucial in UC pathogenesis, particularly through antioxidant defense and immune modulation. The identified six-gene signature offers promising diagnostic and therapeutic potential for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.